Oncology Institute, Inc. (TOI) Stock Price & Analysis

Oncology Institute, Inc. (TOI) fell 2.17% to USD 4.96 as of June 10, 2026 at 03:30 UTC, according to Nexqual real-time market data.

TOI last closed at USD 5.07; the session ranged USD 4.83–5.15 on volume of 1,726,625 shares. Market capitalization is $495.92M, with a 52-week range of USD 2.02–5.58 (NCM). Source: Nexqual, June 10, 2026 at 03:30 UTC.

Key Statistics (as of June 10, 2026 at 03:30 UTC)

PriceUSD 4.96
Change▼ 2.17% (down)
Previous CloseUSD 5.07
OpenUSD 5.06
Day RangeUSD 4.83 – 5.15
52-Week RangeUSD 2.02 – 5.58
Volume1,726,625 shares
Market Cap$495.92M
ExchangeNCM

Technical Analysis (TOI)

Nexqual's technical model rates TOI "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:30 UTC.

Overall SignalSTRONG BUY
RSI (14)66.64 (neutral)
vs SMA50Above (USD 3.87)
MACD0.29 (positive)

Analyst Ratings (TOI)

Wall Street analysts rate TOI "Strong Buy" based on 4 analysts, with a mean price target of USD 7.25 (range USD 5–8), per Nexqual as of June 10, 2026 at 03:30 UTC.

Consensus RatingStrong Buy
Analyst Count4
Mean TargetUSD 7.25
High TargetUSD 8
Low TargetUSD 5
Buy / Hold / Sell4 / 0 / 0

Earnings (TOI)

Next Earnings Date2026-05-07
Revenue Estimate$157.10M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -0.02 vs est -0.09 ▲ beat
2025-12-31USD -0.06 vs est -0.09 ▲ beat
2025-09-30USD -0.14 vs est -0.11 ▼ miss
2025-06-30USD -0.15 vs est -0.12 ▼ miss

Source: Nexqual, June 10, 2026 at 03:30 UTC.

Financials & Fundamentals (TOI)

Total Revenue$545.76M
Revenue Growth (YoY)+41.20%
Gross Margin+15.12%
Operating Margin-4.42%
Profit Margin-7.97%
Current Ratio1.47
Total Cash$30.28M
Total Debt$104.91M
Free Cash Flow$-15.31M

Source: Nexqual, June 10, 2026 at 03:30 UTC.

Financial Health Score (TOI)

Nexqual rates Oncology Institute, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:30 UTC.

GrowthStrong — Revenue +41% YoY (latest Q)
ProfitabilityWeak — Gross margin 15%, operating -4%
Balance SheetMixed — $30M cash vs $105M debt
Cash FlowWeak — FCF negative: -$15M, burning cash
EfficiencyMixed — No data

Ownership (TOI)

Insider Ownership+18.17%
Institutional Ownership+46.05%
Shares Outstanding99.98M
Float87.33M
Short % of Float+7.33%

Source: Nexqual, June 10, 2026 at 03:30 UTC.

Leadership (TOI)

Oncology Institute, Inc. is led by Daniel Virnich FACHE (age 46), CEO & Executive Director, per Nexqual as of June 10, 2026 at 03:30 UTC.

CEO & Executive DirectorDaniel Virnich FACHE (age 46)
Chief Financial OfficerRobert Carter (age 39)
Senior Vice President of FinanceStephen Cella

Major Backers & Investors (TOI)

Notable institutional backers of Oncology Institute, Inc. include Deerfield Management Company, L.P, Kanen Wealth Management LLC, Josh Arnold Investment Consultant, Llc, according to Nexqual as of June 10, 2026 at 03:30 UTC.

Active Investors

InvestorStake
Deerfield Management Company, L.P3.36%
Kanen Wealth Management LLC2.78%
Josh Arnold Investment Consultant, Llc2.46%
Balyasny Asset Management LP1.83%
Wexford Capital LP1.71%
CenterBook Partners LP1.57%

Index Funds (Passive)

FundStake
Vanguard Group7.6%
BlackRock6.9%
Geode Capital1.76%
State Street1.46%

Source: Nexqual, June 10, 2026 at 03:30 UTC.

From Oncology Institute, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
XLOXilio Therapeutics, Inc.USD 7.9▲ 2.6%
BBLGBone Biologics CorpUSD 1.23▼ 1.52%
ICUSeaStar Medical Holding CorporaUSD 2.78▼ 5.44%
LIXTLixte Biotechnology Holdings, IUSD 6.87▼ 1.86%
SABSSAB Biotherapeutics, Inc.USD 3.36▼ 0.59%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:30 UTC. This page is informational and not investment advice.